Defence and space technology company Voyager Technologies (NYSE: VOYG) and space biotechnology company Exobiosphere announced on Wednesday that the companies have signed a mission management contract for operations aboard the International Space Station (ISS), advancing the commercialisation of automated biological research in microgravity for pharmaceutical and biotech applications.

Under the agreement, Voyager Technologies Europe will act as mission integrator for Exobiosphere's Orbital High-Throughput Screener (OHTS), a miniaturised, reusable platform designed for repeated experimental campaigns in orbit. The company will also oversee project management, including NASA Safety Review compliance, ISS integration and coordination of on-orbit operations.

The modular OHTS system enables sample and consumable exchange between missions, creating a continuous research pipeline without the need for repeated hardware deployment. Follow-on contracts are anticipated as part of the programme's expansion.

This partnership reinforces Voyager's role in enabling low-Earth orbit access for commercial research and supports Exobiosphere's strategy to accelerate drug discovery using microgravity-based biological research.